News Story: Full Text
Sponsored By
Gamma Tiles
Please Click On The Above Banner For More Details
Braintumor Website


Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.

Al's Comment:

 This is only in the test tube and in mice, so more research is needed. This is a perfect use of the brain tumor virtual trial... we have 7 patients who used Metformin in addition to Temodar, and they seem to be doing better than average. That is not enough patients to even consider using it but it is a good start. If everyone reading this joined the virtual trial project, we would have enough data to say it is worth using - or not.  Go to and click virtual trial to join and for details. It is free and easy - we do not tell you what to do - we just observe the outcome.

Posted on: 10/11/2015

  Oncotarget. 2015 Sep 26. [Epub ahead of print]
Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo.
Yu Z1, Zhao G1, Xie G2, Zhao L3, Chen Y1, Yu H1, Zhang Z1, Li C4, Li Y1.
Author information:
1Department of Neurosurgery, First Hospital of Jilin University, Changchun, China.
2Department of Obstetrics and Gynecology, First Hospital of Jilin University, Changchun, China.
3Department of Clinical laboratory, Second Hospital of Jilin University, Changchun, China.
4Department of Experimental Pharmacology and Toxicology, School of Pharmacy, Jilin University, Changchun, China.
Glioblastoma (GBM) is the most frequent and aggressive brain tumor in adults. In spite of advances in diagnosis and therapy, the prognosis of patients with GBM has remained dismal. The fast recurrence and multi-drug resistance are some of the key challenges in combating brain tumors. Glioma stem cells (GSCs) which are considered the source of relapse and chemoresistance, the need for more effective therapeutic options is overwhelming. In our present work, we found that combined treatment with temozolomide (TMZ) and metformin (MET) synergistically inhibited proliferation and induced apoptosis in both glioma cells and GSCs. Combination of TMZ and MET significantly reduced the secondary gliosphere formation and expansion of GSCs. We first demonstrated that MET effectively inhibited the AKT activation induced by TMZ, and a combination of both drugs led to enhanced reduction of mTOR, 4EBP1 and S6K phosphorylation. In addition, the combination of the two drugs was accompanied with a powerful AMP-activated protein kinase (AMPK) activation, while this pathway is not determinant. Xenografts performed in nude mice demonstrate in vivo demonstrated that combined treatment significantly reduced tumor growth rates and prolonged median survival of tumor-bearing mice. In conclusion, TMZ in combination with MET synergistically inhibits the GSCs proliferation through downregulation of AKT-mTOR signaling pathway. The combined treatment of two drugs inhibits GSCs self-renewal capability and partly eliminates GSCs in vitro and in vivo. This combined treatment could be a promising option for patients with advanced GBM.


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557